Israeli interventional neurovascular devices developer Rapid Medical has raised $20 million in a Series C financing round.
JAM Capital Partners and MicroPort, which will join Rapid Medical’s board of directors, led the round with participation from Agate JT Ventures, RocSon Medtech Fund and existing investors also joined the round.
Rapid Medical will use the new capital to develop a commercial presence in the U.S. ahead of regulatory approvals and also expand its sales and marketing efforts in Europe.
Additionally, the company intends to use the new funds to develop additional innovative products, and support the completion of TIGER IDE study in the U.S.